ABT · News · 20260813N

Product Launch and Transition

ABBOTT LABORATORIES · 2026-08-13 · Importance 34 · Surprise 42

Wolfe Research identified Abbott’s Volt pulsed-field ablation (PFA) catheter launch as a catalyst for the company’s 2027 medical-device outlook. The firm also cited an expected recovery in Abbott’s Libre continuous glucose-monitoring business. The commentary indicates that new electrophysiology products and improving CGM demand are viewed as potential drivers of Abbott’s competitive positioning in med-tech.

Key facts

• Wolfe Research said Abbott's better 2027 outlook is driven by catalysts like the Volt PFA catheter launch and recovery in Libre continuous glucose monitors. source